Ignite Creation Date:
2024-05-05 @ 7:24 PM
Last Modification Date:
2024-10-26 @ 9:48 AM
Study NCT ID:
NCT00667823
Status:
COMPLETED
Last Update Posted:
2022-02-10
First Post:
2008-04-24
Brief Title:
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status:
COMPLETED
Status Verified Date:
2022-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SERAPHIN OL
Brief Summary:
The main objective of the AC 055 303SERAPHIN OL study which will follow the AC 055 302SERAPHIN study will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None